Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: SVY

Global Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems Market Report 2020-2025 with Profiles of Bristol-Myers Squibb Co., GSK, Hofmann-La Roche, Merck & Co., and Novartis


DUBLIN, Jan. 25, 2021 /PRNewswire/ -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The scope of the report includes an overview of the global market for nanoparticles in biotechnology, drug development, and drug delivery, and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.

The report includes an analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.

Nanoparticle technology has made major advances in particle type, production, and application in all areas of the life sciences in the past two decades. The most rapid advances have been made in the application of nanoparticles in drug research and development, drug product formulation, and development of novel drug delivery systems using nanoparticle carriers. The development of nanoparticles and their rapid incorporation into the research and development, formulation, and production of drug products has given rise to a new area of biotechnology and pharmaceutical research involving particle materials in the nanometer size range.

Nanoparticles used in the life sciences and biomedical applications are usually considered to be in the range of 10 nanometers to 100 nanometers in diameter. Developing particles from various starting materials that remain stable in this size range has become one of the fastest-growing and most potentially useful emerging technologies of the last several decades.

Both particle size and shape are important in the life sciences because the particle properties of biopharmaceutical products can impact a drug product in two ways: size and shape. Size and shape can have an influence on drug performance or efficacy in the body.

The methods for producing nanoparticles vary depending on the starting substrate materials and the size particle desired as a product. This report will provide an overview of various production methods and indicate new advances in the production area. At present, the U.S. holds the largest number of patents in the nanoparticle area. This is largely due to the early commercialization of some nanoparticle products by U.S. companies. It also reflects that the contribution to research and development of new ideas by American companies is larger than those by most other countries.

Europe is the second-largest market for nanoparticle drug technology. France, Germany, and the U.K. are the major contributors to its market share. Drug formulation and delivery are attracting new players in Europe, and this in turn will contribute to the market's growth.

The Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Market Breakdown by Product Type

Chapter 5 Structure of Nanoparticles

Chapter 6 Production of Nanoparticles

Chapter 7 Nanoparticles in Biotechnology

Chapter 8 Nanoparticles in Drug Development and Formulation

Chapter 9 Nanoparticles in Drug Delivery Systems

Chapter 10 In Vitro and In Vivo Diagnostic Imaging

Chapter 11 Biomedical Nanoparticle Products

Chapter 12 Market Breakdown by Region

Chapter 13 Role of Nanotechnology in COVID-19 Vaccine Production

Chapter 14 Patents, Licensing, Mergers, and Acquisitions

Chapter 15 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/rhgcqn

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 07:00
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") for violations of 10(b) and 20(a) of the Securities...

at 07:00
YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

at 06:40
The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation . Shareholders who...

at 06:00
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ....

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...



News published on and distributed by: